Pfizer RSV shot meets goals in trial of high-risk adults under age 60 By Michael Erman (Reuters) – Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adults, for whom the […]
This post first appeared on Global Banking And Finance Review Magazine – Fin, please read the originial post: here
